![Charles York](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles York
Vorstandsvorsitzender bei
MERSANA THERAPEUTICS
Profil
Charles N.
York is currently President, CEO, COO, CFO, and Director at Mersana Therapeutics, Inc. since 2026.
He is also Chief Operating & Financial Officer at DOT Therapeutics-2, Inc. and Day One Biopharmaceuticals, Inc., both positions held since 2021.
Formerly, Mr. York was Controller at Astrotech Corp.
from 2009 to 2012.
From 2015 to 2021, served as Chief Financial Officer, Secretary, and VP at Spyre Therapeutics, Inc. Education includes an undergraduate degree from the University of Connecticut in 1999 and an MBA from McCombs School of Business in 2006.
Aktive Positionen von Charles York
| Unternehmen | Position | Beginn |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Finanzdirektor/CFO | 01.02.2021 |
| MERSANA THERAPEUTICS | Vorstandsvorsitzender | 06.01.2026 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drugs | Finanzdirektor/CFO | 17.02.2021 |
Ehemalige bekannte Positionen von Charles York
| Unternehmen | Position | Ende |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Finanzdirektor/CFO | 12.02.2021 |
| ASTROTECH CORPORATION | Comptroller/Controller/Auditor | 01.08.2012 |
Ausbildung von Charles York
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
68
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Astrotech Corp.
 Astrotech Corp. Aerospace & DefenseElectronic Technology Develops, manufactures and sells trace detectors | Electronic Technology |
Mersana Therapeutics, Inc.
 Mersana Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures antibody drug conjugates to improve patient outcomes in multiple oncology indications | Health Technology |
Spyre Therapeutics, Inc.
 Spyre Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
University of Connecticut
 University of Connecticut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
McCombs School of Business
 McCombs School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drugs | Health Technology |
Day One Biopharmaceuticals, Inc.
 Day One Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops and commercializes targeted therapies for cancers | Health Technology |
